The aminobisphosphonate risedronate preserves localized mineral and material properties of bone in the presence of glucocorticoids

Arthritis and Rheumatism

Volumn 56, Issue 11, 2007, Pages 3726-3737

  Balooch, Guive ^a,b   Yao, Wei ^c   Ager, Joel W ^a   Balooch, Mehdi ^b   Nalla, Ravi K ^a   Porter, Alexandra E ^d   Ritchie, Robert O ^a   Lane, Nancy E ^b,c  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CREATININE; DEOXYPYRIDINOLINE; GLUCOCORTICOID; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; PREDNISOLONE; RISEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BIOMECHANICS; BONE MARROW BIOPSY; BONE MASS; BONE MINERAL; BONE MINERALIZATION; BONE STRENGTH; BONE TURNOVER; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; ILIAC CREST; MALE; MICRO-COMPUTED TOMOGRAPHY; MICROSCOPE; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; TOMOGRAPHY; TRABECULAR BONE; TRANSMISSION ELECTRON MICROSCOPY; X RAY; X RAY CRYSTALLOGRAPHY;

ANIMALS; BIOMECHANICS; BIOPSY; BONE DENSITY CONSERVATION AGENTS; CALCIFICATION, PHYSIOLOGIC; DRUG INTERACTIONS; ELASTICITY; ETIDRONIC ACID; GLUCOCORTICOIDS; HUMANS; ILIUM; LUMBAR VERTEBRAE; MALE; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; PREDNISOLONE; TOMOGRAPHY, X-RAY;

EID: 36049044103     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22976     Document Type: Article

References (36)

1. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995;54:49-52.
2. Lane NE. An update on glucocorticoid-induced osteoporosis [review]. Rheum Dis Clin North Am 2001;27:235-53.
3. Saag KG. Glucocorticoid-induced osteoporosis [review]. Endocrinol Metab Clin North Am 2003;32:135-57, vii.
4. Delaney MF, Hurwitz S, Shaw J, LeBoff MS. Bone density changes with once weekly risedronate in postmenopausal women. J Clin Densitom 2006;6:45-50.
5. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-7.
6. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051-6.
7. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al, for the Glucocorticoid-induced Osteoporosis Intervention Study Group. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-9.
8. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the Fracture Intervention Trial. J Bone Miner Res 2004;19:1250-8.
9. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999;42:2309-18.
10. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67:277-85.
11. Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP. Primary prevention of glucocorticoid-induced osteoporosis with intravenous Pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 2001;16:104-12.
12. Eastell R, Devogelaer JP, Peel NF, Chines AA, Bax DE, Sacco-Gibson N, et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos lnt 2000;11:331-7.
13. Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000;15:1467-76.
14. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581-9.
15. Reszka AA, Halasy-Nagy JM, Masarachia PJ, Rodan GA. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis: a link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem 1999;274:34967-73.
16. Asahi H, Mizokami A, Miwa S, Keller ET, Koshida K, Namiki M. Bisphosphonate induces apoptosis and inhibits pro-osteoclastic gene expression in prostate cancer cells. Int J Urol 2006;13:593-600.
17. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999;104:1363-74.
18. Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T, et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 2002;109:1041-8.
19. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Guide S, Wu W, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006;38:617-27.
20. Lane NE, Yao W, Balooch M, Nalla RK, Balooch G, Habelitz S, et al. Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res 2006;21:466-76.
21. Yao W, Balooch G, Balooch M, Jiang Y, Nalla RK, Kinney J, et al. Sequential treatment of ovariectomized mice with bFGF and risedronate restored trabecular bone microarchitecture and mineralization. Bone 2006;39:460-9.
22. Yao W, Hadi T, Jiang Y, Lotz J, Wronski TJ, Lane NE. Basic fibroblast growth factor improves trabecular bone connectivity and bone strength in the lumbar vertebral body of osteopenic rats. Osteoporos Int 2005;16:1939-47.
23. Kinney JH, Haupt DL, Balooch M, Ladd AJ, Ryaby JT, Lane NE. Three-dimensional morphometry of the L6 vertebra in the ovariectomized rat model of osteoporosis: biomechanical implications. J Bone Miner Res 2000;15:1981-91.
24. Parfitt AM. Bone histomorphometry: standardization of nomenclature, symbols and units (summary of proposed system). Bone 1988;9:67-9.
25. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987;2:595-610.
26. Balooch G, Marshall GW, Marshall SJ, Warren OL, Asif SA, Balooch M. Evaluation of a new modulus mapping technique to investigate microstructural features of human teeth. J Biomech 2004;37:1223-32.
27. Engqvist H, Botton GA, Couillard M, Mohammadi S, Malmstrom J, Emanuelsson L, et al. A novel tool for high-resolution transmission electron microscopy of intact interfaces between bone and metallic implants. J Biomed Mater Res A 2006;78:20-4.
28. Porter AE, Buckland T, Hing K, Best SM, Bonfield W. The structure of the bond between bone and porous silicon-substituted hydroxyapatite bioceramic implants. J Biomed Mater Res A 2006;78:25-33.
29. Fratzl P, Schreiber S, Klaushofer K. Bone mineralization as studied by small-angle x-ray scattering. Connect Tissue Res 1996;34:247-54.
30. Akhter MP, Cullen DM, Gong G, Recker RR. Bone biomechanical properties in prostaglandin EP1 and EP2 knockout mice. Bone 2001;29:121-5.
31. Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, et al. Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 2006;116:2152-60.
32. Borah B, Dufresne TE, Ritman EL, Jorgensen SM, Liu S, Chmielewski PA, et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone 2006;39:345-52.
33. Faibish D, Ott SM, Boskey AL. Mineral changes in osteoporosis: a review. Clin Orthop Relat Res 2006;443:28-38.
34. Monier-Faugere MC, Geng Z, Paschalis EP, Qi Q, Arnala I, Bauss F, et al. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J Bone Miner Res 1999;14:1768-78.
35. Rohanizadeh R, LeGeros RZ, Bohic S, Pilet P, Barbier A, Daculsi G. Ultrastructural properties of bone mineral of control and tiludronate-treated osteoporotic rat. Calcif Tissue Int 2000;67:330-6.
36. Chavassiuex PM, Arlot ME, Roux JP, Portero N, Daifotis A, Yates J, et al. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. J Bone Miner Res 2000;15:754-62. Vol. 56, No. 11, November 2007, pp 3738-3747